The HKU Department of Ophthalmology is honoured to have Professor Tony Mok as our orator of the Distinguished Lecture Series.
Date : Oct 11, 2021 (Monday)
Time : 7:00 – 8:00 p.m.
Venue : Cheung Kung Hai Lecture Theatre 1 (LT1) at William M W Mong Block
(G/F, Lecture Theatre 1, William M.W. Mong Block, Faculty of Medicine Building, 21 Sassoon Road, Pokfulam, Hong Kong)
All are welcome, on a first come first serve basis
For HKU members (HKU Portal login is required): https://hkuems1.hku.hk/hkuems/ec_hdetail.aspx?ueid=78434
For non-HKU guests: https://hkuems1.hku.hk/hkuems/ec_hdetail.aspx?guest=Y&ueid=78434
Professor Mok is the Li Shu Fan Medical Foundation Named Professor of Clinical Oncology and Chair of Clinical Oncology at The Chinese University of Hong Kong (Hong Kong). He underwent medical studies at the University of Alberta, Canada, and subsequently underwent training as an oncological physician at the Princess Margaret Cancer Centre in Toronto, Canada. In 1996, he returned to Hong Kong to embark on highly productive and impactful academic career at the Chinese University of Hong Kong. His main research interest focuses on biomarker and molecular targeted therapy in lung cancer. Professor Mok’s first major breakthrough came when serving as principal investigator for the IRESSA Pan-Asia Study (IPASS), a landmark trial that established the role of first-line gefitinib in patients with EGFR mutation. The publication of this trial in the New England Journal of Medicine in 2009 kick started the field of Precision Medicine, now a highly important topic that is taught in medical schools worldwide. Professor Mok has also led the way in immunotherapy for cancer patients, demonstrating the role for single immunotherapy in patients with high expression of PD-L1 protein. This subsequently paved the way for the United States Food and Drug Administration approving immunotherapy for clinical use in cancer therapy in 2019. Most recently in 2020, Professor Mok’s team published the world’s first-in-human Phase I clinical trial investigating the safety and feasibility of CRISPR gene-edit therapy in patients with end-stage lung cancer.
Prof. Mok has contributed to over 250 articles in international peer-reviewed journals, including the New England Journal of Medicine, Science and the Lancet. He is now Fellow of American Society of Clinical Oncology (FASCO), Past Chair of the ASCO International Affairs Committee, Treasurer and Past President of the International Association for the Study of Lung Cancer (IASLC), a member of the ASCO Publications Committee and Vice Secretary of the Chinese Society of Clinical Oncology (CSCO). For his immense impact in oncology, Professor Mok was recognized as a ‘Giant of Cancer Care’ by OncLive in 2020.
In this lecture, Professor Mok will share insights into how to design and coordinate international clinical trials to make a lasting impact on patient care.